MEDICAL-TREATMENT OF HEPATOCELLULAR-CARCINOMA - ANY PROGRESS

被引:30
作者
COLLEONI, M
GAION, F
LIESSI, G
MASTROPASQUA, G
NELLI, P
MANENTE, P
机构
[1] OSPED CIVILE,DEPT RADIOL,I-30133 CASTELFRANCO VENE,ITALY
[2] OSPED CIVILE,DIV MED 1,I-30133 CASTELFRANCO VENE,ITALY
关键词
HEPATOCELLULAR CARCINOMA; MEDICAL TREATMENT;
D O I
10.1177/030089169408000501
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hepatocellular carcinoma (HCC) remains one of the most common neoplasms worldwide. Curative treatment options include liver transplantation or resection. Unfortunately, most patients still have unresectable or untransplantable HCC due to disease extension or comorbid factors and are therefore candidate only for palliative treatments. Methods: In this review we have analyzed the different medical approaches employed in the treatment of HCC in an attempt to better define their roles. Results: Palliative medical treatments including systemic chemotherapy, immunotherapy or hormonal manipulation rarely influence survival of the patients. Although a high response rate is often reported with new local therapies such as transcatheter arterial embolization, intraarterial chemotherapy or percutaneous ethanol injection, the real impact of these treatment modalities on patient survival remains to be determined. Conclusion: One way to improve the diagnosis of HCC patients would be an appropriate approach to evaluate new drugs or treatment modalities. To answer all the open questions, further trials, possibly randomized, should be conducted on a substantial number of patients with homogeneous prognostic factors.
引用
收藏
页码:315 / 326
页数:12
相关论文
共 162 条
  • [1] ALIDRISSI HY, 1985, HEPATO-GASTROENTEROL, V32, P8
  • [2] HEPATIC-ARTERY LIGATION AND CHEMOTHERAPEUTIC INFUSION IN THE TREATMENT OF HEPATIC MALIGNANCY
    ALJURF, AS
    JOCHIMSEN, PR
    SHIRAZI, SS
    ZIKE, WL
    URDANETA, LF
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1984, 27 (02) : 119 - 123
  • [3] ALSARRAF M, 1974, CANCER-AM CANCER SOC, V33, P574, DOI 10.1002/1097-0142(197402)33:2<574::AID-CNCR2820330237>3.0.CO
  • [4] 2-A
  • [5] AMREIN PC, 1984, CANCER TREAT REP, V68, P923
  • [6] ANDO K, 1987, Cancer Chemotherapy and Pharmacology, V19, P183
  • [7] [Anonymous], 1990, Cancer, V66, P135
  • [8] ANSFIELD F, 1971, CANCER, V23, P1147
  • [9] ANSFIELD FJ, 1975, CANCER-AM CANCER SOC, V36, P2413, DOI 10.1002/1097-0142(197512)36:6<2413::AID-CNCR2820360621>3.0.CO
  • [10] 2-3